The day after his disciplinary dismissal of Tokyo University for "damaging the honor or the university's credibility "Hisashi Moriguchi maintained in an interview with science Insider that he has really contributed to a revolutionary experience to treat a patient with heart disease with cardiac muscle cells derived from induced pluripotent own patient's stem (iPS) cells. He admitted making mistakes, and there is doubt on its claims. But for this one case, "I'm very confident," he said.
At a meeting of two hours-plus at a hotel in Tokyo on October 20, Moriguchi was polite, friendly and relaxed , despite being unhappy with how he was rejected by Todai, as the University of Tokyo is known. he noted that he had promised to cooperate with the investigations now under way to determine what happened and the possible misuse of research funds. "I had said that whatever the judgment of the committee, I will resign to take responsibility for causing trouble," he said. But, "Even before these committees reached conclusions, the University of Tokyo suddenly decided on a disciplinary dismissal, "he added. He said he wanted to keep his job long enough to produce a proof of interest for investigators to his computer and files in his laboratory at the Todai hospital. But with the cut off access, "it will be very difficult to cooperate," although he said he intends to do the best he can.
Moriguchi also disappointed his coauthors are deserting. Some have asked publishers to remove their names papers; others say they do not see the final versions of some papers on their names. Moriguchi insisted that for all the several articles in which he was the corresponding author, he always showed them to her co-authors. He stressed that he was primarily responsible for the reported work, but turned to his colleagues for discussion and advice. Those who do not wish to be listed as co-authors should have said so, he said. It heard to ask co-authors to have their names removed from contributions to the Exchange protocol read about it in the Japanese press. "I am shocked," he said. "At least they should have contacted the corresponding author," he said.
He admitted making mistakes. An identical statement in two articles published online this year Scientific Reports reads: "The study was approved by the Institutional Review Board of our institutions." On one of the documents of Harvard Medical School and the University of Tokyo are listed in parentheses. Another document lists these institutions and medical and dental Tokyo University (TMDU). Moriguchi said he has not received approval from the review board. He said he thought it was a fine line on the approval of the draft board was necessary for the research described. Including the declaration on paper "was a failure of the procedure," he said. He added that he has already informed Scientific Reports he would return the papers.
Moriguchi also wants to correct misunderstandings about his affiliations. Contrary to the statements of Harvard University, he was a visiting scientist for only one month at the end of 1999, Moriguchi insists he spent a full year there as a visiting scientist from November 1999 to November 00 and then established an affiliation continues in 06. He showed a letter signed in February 06 by Raymond Chung, director of hepatology header logos and addresses of Massachusetts General Hospital and Harvard Medical School, informing that Moriguchi "when you visit here, you will have appointed guest speaker, Harvard medical School, and Consultant in medicine, Massachusetts General Hospital, after arrival here."
despite the "while visit "sentence Moriguchi insisted he was a current position. (Says a spokesperson for MGH, Susan McGreevey, Science he was appointed temporarily to facilitate the participation of Moriguchi in a 06 event when Moriguchi is not present, the appointment was immediately canceled and technically lasted only one day.) Moriguchi also submitted a request in July 2011 patent for "Methods and compositions for cell reprogramming," who calls himself and Chung as the inventors and designated assignee as "the General Hospital Corporation, Boston, MA, "the MGH legal entity. (McGreevey said the application is withdrawn.) "If I had no connection (at MGH and Harvard) they would not file a patent application," he said.
He also explained that he acquired the expertise to conduct sophisticated experiments in cell biology by studying and working on his own. with an undergraduate degree in nursing and in health promotion a Masters, completed in 1995 from TMDU, Moriguchi first worked for reflection on health policy in Tokyo, and in August 1999 joined the University of Tokyo research Center for Advanced science and technology, where he worked on issues policy related to the evaluation of drugs and medical economics. he said he realized in 06, he wanted to meet the challenge of developing innovative drugs himself. he said he rented a room near the campus, set up a laboratory, and himself taught experimental techniques. Later, it maintained a similar arrangement in a rented facility in the Boston area where he worked by himself on iPS cells, the development of a method of creating iPS cells from somatic cells using chemical products. He funded the research of his own pocket, he said. At one point he said he cultivated heart cells derived from pig iPS cells and then a collaborator, he refused to identify the transplanted pig. After the experience of pork well, he used his center area of Boston culture 30 million heart muscle cells which, according to him, were injected into a heart disease patient in mid-2011. He believes the patient is doing well. But he said his surgeon collaborator, he declined to name, cut the contact for unknown reasons. "Maybe because of the publicity," said Moriguchi.
Moriguchi agreed that his strange story "is hard to believe, as he is. That's why I want to gather and present evidence. "
0 Komentar